A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection

Activo, no reclutaFase 3ClinicalTrials.gov

ID: NCT05120349RENIS: IS003791Tipo: INTERVENTIONALInicio: 21 de feb de 2022Fin estimado: 1 de nov de 2032

Traducción no disponible, mostrando original

Resumen

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Descripción detallada

This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R). Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Stage IA2 or IA3 disease, based on TNM8 classification.
Male or female, at least ≥ 18 years.
NSCLC, of non-squamous histology.
Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection.
Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
World Health Organization performance status of 0 or 1.
Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.
Minimum life expectancy of \> 6 months.
Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.

Criterios de exclusión

Mixed small cell and non-small cell cancer history.
Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection.
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection.
History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
Any of the following cardiac criteria:
Mean resting QTcF interval \> 470 ms, obtained from triplicate ECGs performed at screening.
Any abnormalities in rhythm, conduction, or morphology of resting ECG,
Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events.
History of interstitial lung disease.
Inadequate bone marrow reserve or organ function.
Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.
Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.

Intervenciones

drug

Osimertinib

The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.

drug

Placebo

Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.

Ubicaciones

Research Site

S.C. de Bariloche, Argentina

Research Site

Rosario, Argentina

Research Site

Buenos Aires, Argentina

Research Site

CABA, Argentina

Research Site

Cipolletti, Argentina

Research Site

La Plata, Argentina

Research Site

Rosario, Argentina

Patrocinadores

PrincipalAstraZeneca

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase III, Double-blind, Randomised, Placebo-Controlled... | EligiMed